• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

I-Flow to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference Tuesday, November 27, 2007 at 8:30 A.M. EST

Posted on: Tuesday, 20 November 2007, 12:00 CST

I-FLOW CORPORATION (NASDAQ:IFLO) announced today that it will address institutional shareholders at the Lazard Capital Markets Fourth Annual Healthcare Conference, Tuesday morning, November 27, 2007 at 8:30 a.m. EST.

The Lazard conference will take place November 27th and 28th at The New York Palace Hotel, New York, NY. Donald M. Earhart, I-Flow's Chairman, President, and Chief Executive Officer, will make a presentation featuring the Company's growth strategies and market opportunities.

I-Flow Corporation is an emerging leader in post-surgical pain relief and is redefining recovery following surgery. The Company's flagship ON-Q® PainBuster® Post-Op Pain Relief System provides targeted pain relief after surgery only where the body needs it, automatically delivering a non-narcotic, pain-numbing medication directly to an incision site for up to five days. The anesthetic is administered through a specially-designed, proprietary catheter -- like the ON-Q SilverSoakerTM which offers enhanced antimicrobial properties to reduce the risk of infection by providing an added layer of protection -- inserted by a surgeon during surgery. ON-Q PainBuster is cleared for use by the U.S. Food & Drug Administration (FDA) and is labeled to reduce pain significantly better than narcotics and to significantly reduce narcotics intake after surgery. Additionally, evidence is mounting that ON-Q PainBuster, by documenting an infection reduction capability, may be a broader surgical site care device. Hospitals saw infection rates more than halved in a new study that was recently announced.

You can access a live webcast and slides of the presentation, after registration, from the Investors link or the Investors' Event Calendar link at www.IFLO.com. The webcast will be available for replay at approximately 9:10 a.m. EST at this same internet address for approximately 90 days. Audio streams require Windows Media Player installations.

About I-Flow

I-Flow Corporation (www.IFLO.com) designs, develops and markets technically advanced, low cost drug delivery systems and services that are redefining the standard of care by providing life enhancing, cost effective solutions for pain relief.

"Safe Harbor" Statement

Certain disclosures made by the Company in this press release and in other reports and statements released by the Company are and will be forward looking in nature, such as comments that express the Company's opinions about trends and factors that may impact future operating results. Disclosures that use words such as the Company "believes", "anticipates", or "expects" or use similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to differ from those expected, and readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to republish revised forward-looking statements to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures made by the Company in this release, which seek to advise interested parties of the risks, and other factors that affect the Company's business, as well as in the Company's periodic reports on Forms 10-K, 10-Q and 8-K filed with the Securities and Exchange Commission. The risks affecting the Company's business include, among others: successful consummation of the previously announced sale of InfuSystem, Inc; physician acceptance of infusion-based therapeutic regimens; implementation of our direct sales strategy; dependence on our suppliers and distributors; reliance on the success of the home health care industry; our continuing compliance with applicable laws and regulations, such as the Food, Drug and Cosmetic Act, and the FDA's concurrence with our management's subjective judgment on compliance issues; the reimbursement system currently in place and future changes to that system; competition in the industry; economic and political conditions in foreign countries; currency exchange rates; inadequacy of booked reserves; technological changes; and product availability and acceptance. All forward-looking statements, whether made in this release or elsewhere, should be considered in context with the various disclosures made by the Company about its business.

Source: Business Wire

More News in this Category